I-03 Yumi Yamamoto Toward a generic PBPK model to predict drug distribution in human brain Wednesday 10:20-11:50 |
I-25 Abhishek Gulati Modeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis Wednesday 10:20-11:50 |
I-35 Xiao Hu Exposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Wednesday 10:20-11:50 |
I-36 Kimberley Jackson Population Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats. Wednesday 10:20-11:50 |
I-43 Marija Jovanovic Effect of Valproic Acid Daily Dose on Phenobarbital Clearance - Nonlinear Mixed Effects Modelling Approach Wednesday 10:20-11:50 |
I-44 Rasmus Juul Kildemoes How Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain management Wednesday 10:20-11:50 |
I-47 Mats Karlsson Item response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia Wednesday 10:20-11:50 |
I-58 Mads Kreilgaard Study design optimization of a morphine analgesia trial using PKPD modelling and simulation Wednesday 10:20-11:50 |
II-02 Celine M. Laffont Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients. Wednesday 15:10-16:30 |
III-01 João Abrantes A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during Video-EEG monitoring Thursday 10:05-11:30 |
III-02 Oliver Ackaert Quantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model Thursday 10:05-11:30 |
III-04 Ricardo Alvarez Differences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly? Thursday 10:05-11:30 |
III-19 Irina Bondareva Population modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data Thursday 10:05-11:30 |
III-40 Jae Yong Chung Ethnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer's Disease Thursday 10:05-11:30 |
IV-09 Shinji Shimizu PBPK modeling of CNS distribution for risperidone and its active metabolite, paliperidone Thursday 15:15-16:40 |
IV-24 Amit Taneja Development of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats Thursday 15:15-16:40 |
IV-25 Paulo Teixeira Population Pharmacokinetic Model of Valproic Acid in Adult Patients: an Update Thursday 15:15-16:40 |
IV-30 Iñaki F. Trocóniz Population pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects Thursday 15:15-16:40 |
IV-35 Sven van Dijkman A PKPD Hidden Markov Model for Lamotrigine in all age groups Thursday 15:15-16:40 |
IV-37 Eline van Maanen Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys. Thursday 15:15-16:40 |
IV-40 Marc Vandemeulebroecke Identifying neuropsychological domains with high information on early signs of cognitive decline: An application of Item Response Theory in the Basel Study on the Elderly Thursday 15:15-16:40 |
IV-41 Nieves Velez de Mendizabal Analysis of Sleep Changes Induced by Citalopram: A Population Approach Thursday 15:15-16:40 |
IV-44 Shaonan Wang Exposure-response analysis of Axomadol in patients suffering from hip and/or knee-joint osteoarthritis pain Thursday 15:15-16:40 |
IV-57 Li Zhu Population Pharmacokinetic/Pharmacodynamic Models for the Heart Rate Effects of BMS-820836, a Triple Monoamine Reuptake Inhibitor, in a Thorough QT Study Thursday 15:15-16:40 |